权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeting Syk to enhance anti-tumor immune responses in neuroblastoma

靶向 Syk 增强神经母细胞瘤的抗肿瘤免疫反应

基本信息

批准号：
10614645
负责人：
Shweta Joshi
金额：
$ 39.88万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-01 至 2026-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10614645
关键词：
Bone Marrow CD8-Positive T-Lymphocytes Cell Line Cells Cephalic Child Childhood Extracranial Solid Tumor Clinical Combined Modality Therapy Data Disease Failure Genetic Genetic Transcription Goals Histology Hypoxia Inducible Factor Immune Immune checkpoint inhibitor Immunologic Memory Immunologic Stimulation Immunologics Immunooncology Immunosuppression Immunotherapy Implant In Vitro Infiltration Inflammatory Innate Immune Response Interleukin-10 Knockout Mice Knowledge Laboratories MYCN gene Macrophage Malignant Childhood Neoplasm Mediating Molecular Monoclonal Antibodies Mus Mutation Myelogenous Neoplasm Metastasis Neuroblastoma Oncogenes Patient-Focused Outcomes Patients Phenotype Phosphotransferases Ploidies Population Prognosis Progressive Disease Radiation therapy Regulation Research Resistance Role SYK gene Signal Pathway Signal Transduction T cell response T-Lymphocyte Testing Transforming Growth Factor beta Treatment Failure Tumor Promotion Tumor-associated macrophages Tyrosine Kinase Inhibitor adaptive immune response adaptive immunity anti-PD-1 anti-PD-L1 anti-tumor immune response arginase checkpoint therapy combinatorial cytotoxic cytotoxic CD8 T cells driving force enhancer binding protein high risk high risk population hypoxia inducible factor 1 immune cell infiltrate immune checkpoint blockade improved improved outcome mouse model neoplastic cell novel novel therapeutic intervention novel therapeutics patient stratification pediatric patients pharmacologic predict responsiveness recruit standard care standard of care synergism transcriptomics tumor tumor growth tumor microenvironment tumor progression tumor-immune system interactions

项目摘要

PROJECT SUMMARY/ABSTRACT: There is critical need to develop novel therapies for neuroblastoma (NB). NB is the most common extracranial pediatric cancer and even after aggressive multimodal treatments, high-risk patients succumb to progressive disease. One of the reasons underlying failure of these therapies in NB is the highly immunosuppressive tumor microenvironment generated by tumor associated macrophages (TAMs) that inhibit both innate and adaptive immune responses. The long-term goal is to better understand the signaling mechanisms by which TAMs mediate tumor immunosuppression and inhibit anti-tumor immune responses in high-risk NB. The overall objectives in this particular application are 1) to determine the role of spleen tyrosine kinase (Syk) in macrophage (MΦ)-mediated immunosuppression in MYCN and non-MYCN amplified (MYCN-NA) NB tumors and 2) to test whether Syk inhibitors combined with immune checkpoint inhibitors or standard care of therapies can improve anti-tumor immune responses in NB. The central hypothesis motivating this research is that Syk in immunosuppressive TAMs inhibits T cell responses and promotes resistance to checkpoint inhibitors in mouse models of NB. This hypothesis has been formulated on the basis of evidences generated in our laboratory utilizing Syk inhibitors and Syk-/- murine models for immuno-oncology. The rationale for the proposed research is that understanding molecular mechanisms by which Syk promote immunosuppression in MYCN and non- MYCN amplified (MYCN-NA) tumors has the potential to identify an immunological signature which will predict responsiveness to Syk inhibitors in NB tumors driven by a Syk-MΦ-dependent immunosuppressive TME. Guided by strong preliminary data, this hypothesis will be tested by pursuing three specific aims: in Aim 1, we will evaluate the effects of myeloid Syk deficiency on NB tumor microenvironment and infiltrating immune populations. In Aim 2, we will investigate molecular mechanisms by which Syk regulate immunosuppressive MΦ polarization in MYCN and MYCN-NA NB tumors. In Aim 3, we will determine whether Syk inhibitors in combination with checkpoint blockade or current therapies can augment anti-tumor immune responses in NB. The significance of our proposal lies in our capacity to develop novel combinatorial therapy of Syk inhibitors with immunotherapy or standard of care therapies that is more effective than current therapies in NB.

项目总结/文摘: